公开(公告)号：US11998577B2

公开(公告)日：2024-06-04

申请号：US17682051

申请日：2022-02-28

申请人： ABBOTT LABORATORIES

发明人： Alejandro Barranco Perez ,  Maria Ramirez Gonzalez ,  Rachael Buck ,  Enrique Vazquez Hernandez

IPC分类号： A61K35/747 ,  A23L33/00 ,  A23L33/125 ,  A23L33/135 ,  A23L33/15 ,  A61K9/107 ,  A61K31/015 ,  A61K31/047 ,  A61K31/07 ,  A61K31/122 ,  A61K31/14 ,  A61K31/145 ,  A61K31/205 ,  A61K31/355 ,  A61K31/405 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/702 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/714 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K35/20 ,  A61K35/745 ,  A61K47/02 ,  A61K47/12 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44 ,  A61K47/46 ,  A61P1/14

CPC分类号： A61K35/747 ,  A23L33/125 ,  A23L33/135 ,  A23L33/15 ,  A23L33/40 ,  A61K9/107 ,  A61K31/015 ,  A61K31/047 ,  A61K31/07 ,  A61K31/122 ,  A61K31/14 ,  A61K31/145 ,  A61K31/205 ,  A61K31/355 ,  A61K31/405 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/702 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/714 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K35/20 ,  A61K35/745 ,  A61K47/02 ,  A61K47/12 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44 ,  A61K47/46 ,  A61P1/14 ,  A23V2002/00

摘要： Disclosed are nutritional compositions including 2′-fucosyllactose (2′-FL) in combination with lutein and RRR-alpha-tocopherol. The nutritional compositions are useful for improving at least one of gut function, health, and development in an individual. In certain embodiments, the nutritional compositions can improve growth or maturation of the gut, as well as promote a healthy balance of beneficial bacteria in the gastrointestinal tract thereby treating and/or preventing formula intolerance or other gastrointestinal diseases and/or disorders resulting from suboptimal gastrointestinal flora population/balance.

公开(公告)号：US20240116974A1

公开(公告)日：2024-04-11

申请号：US18345903

申请日：2023-06-30

申请人： Primmune Therapeutics, Inc.

发明人： Stephen E. WEBBER ,  James Richard APPLEMAN

IPC分类号： C07H19/16 ,  A61K31/708 ,  A61K45/06

CPC分类号： C07H19/16 ,  A61K31/708 ,  A61K45/06

摘要： The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.

公开(公告)号：US11850258B1

公开(公告)日：2023-12-26

申请号：US16887951

申请日：2020-05-29

申请人： Nilesh B. Karalkar ,  Steven A. Benner

发明人： Nilesh B. Karalkar ,  Steven A. Benner

IPC分类号： A61K31/708 ,  C12P19/34 ,  A61K31/7072 ,  A61K31/7068 ,  A61K31/7076

CPC分类号： A61K31/708 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  C12P19/34

摘要： This invention claims ribonucleosides and their derivatives, including triphosphates, that have a 3′-ONH2 moiety instead of a 3′-OH moiety.

公开(公告)号：US20230310469A1

公开(公告)日：2023-10-05

申请号：US18023600

申请日：2021-08-30

申请人： Accencio LLC

发明人： Kevin Brown ,  Kevin Brogle

IPC分类号： A61K31/683 ,  A61K31/708 ,  A61K31/55 ,  A61K31/4375 ,  A61K31/522 ,  A61K9/00

CPC分类号： A61K31/683 ,  A61K31/708 ,  A61K31/55 ,  A61K31/4375 ,  A61K31/522 ,  A61K9/0014

摘要： The present disclosure relates to methods of treating at least one symptom of a coronavirus infection, or preventing an acute inflammatory response, e.g., a cytokine storm in a coronavirus patient, in particular a SARS-CoV-19 patient, by administering a Toll-Like-Receptor (TLR) agonist, in particular a TLR-7 or TLR-8 agonist.

公开(公告)号：US11707508B2

公开(公告)日：2023-07-25

申请号：US16679425

申请日：2019-11-11

申请人： ARES TRADING S.A. ,  Nicolas Chomont ,  Jean-Pierre Routy

发明人： Alena Zalutskaya ,  John Gourley ,  Nicolas Chomont ,  Jean-Pierre Routy ,  Steven Deeks

IPC分类号： A61K38/27 ,  A61P31/18 ,  A61K31/52 ,  A61K31/708 ,  A61K31/7068 ,  A61K31/341 ,  A61K31/675 ,  A61K31/496 ,  A61K31/536 ,  A61K31/505 ,  A61K31/551 ,  A61K31/7072

CPC分类号： A61K38/27 ,  A61K31/341 ,  A61K31/496 ,  A61K31/505 ,  A61K31/52 ,  A61K31/536 ,  A61K31/551 ,  A61K31/675 ,  A61K31/708 ,  A61K31/7068 ,  A61K31/7072 ,  A61P31/18

摘要： The subject invention pertains to methods of treating HIV-1 infected subject comprising the administration of growth hormone to a subject infected by HIV-1. The subject may be undergoing co-administration of anti-retroviral therapies (ARTs), may be untreated with anti-retroviral drugs (ARDs) or may be in a period of time where no ART is being administered. Growth hormone may be administered at a fixed dosage for a set period of time or may be administered at a first dosage for a first period of time that may then be increased or decreased to a second dosage for a second period of time.

公开(公告)号：US20230190876A1

公开(公告)日：2023-06-22

申请号：US17911891

申请日：2021-03-18

申请人： GI INNOVATION, INC.

发明人： Myung Ho JANG ,  Su Youn NAM ,  Young Jun KOH

IPC分类号： A61K38/20 ,  A61K38/17 ,  A61K45/06 ,  A61P35/00 ,  A61K39/395 ,  A61K31/4709 ,  A61K31/444 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/708 ,  A61K31/337 ,  A61K33/243 ,  A61K31/506 ,  A61K31/519

CPC分类号： A61K38/2013 ,  A61K38/1774 ,  A61K45/06 ,  A61P35/00 ,  A61K39/3955 ,  A61K31/4709 ,  A61K31/444 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/708 ,  A61K31/337 ,  A61K33/243 ,  A61K31/506 ,  A61K31/519

摘要： A pharmaceutical composition containing, as active ingredients, a fusion protein including an IL-2 protein and a CD80 protein, and an anticancer agent is disclosed. A fusion protein including a CD80 fragment, an immunoglobulin Fc, and an IL-2 variant, can activate immune cells such as natural killer cells, and at the same time, can control the immune cell regulatory activity of regulatory T cells. In addition, when an anticancer agent is administered in combination with the fusion protein, cancer can be effectively inhibited. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein of an IL-2 protein and a CD80 protein, and an anticancer agent can increase the immune activity in the body and can be effectively utilized not only for cancer but also for an infectious disease, and thus has high industrial potential.

公开(公告)号：US11633418B2

公开(公告)日：2023-04-25

申请号：US17242862

申请日：2021-04-28

申请人： The Trustees of Columbia University in the City of New York

发明人： Michio Hirano ,  Caterina Garone

IPC分类号： A01N43/04 ,  A61K31/70 ,  A61K31/7072 ,  A61K31/708 ,  A61K31/7068 ,  A61K31/7076

摘要： The invention relates generally to a pharmacological therapy for a human genetic diseases, specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxyribonucleoside monophosphate, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine monophosphate (dTMP) or deoxycytidine monophosphate (dCMP), or mixtures thereof. This molecular bypass approach is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome.

公开(公告)号：US11591341B2

公开(公告)日：2023-02-28

申请号：US16849851

申请日：2020-04-15

申请人： ALIGOS THERAPEUTICS, INC.

发明人： Sandrine Vendeville ,  Pierre Jean-Marie Bernard Raboisson ,  Yannick Debing

IPC分类号： C07D487/04 ,  C07D487/14 ,  C07D491/22 ,  A61K31/4985 ,  A61K31/551 ,  A61P31/20 ,  A61K31/675 ,  A61K31/683 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/708 ,  A61K38/21

摘要： Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220313715A1

公开(公告)日：2022-10-06

申请号：US16306183

申请日：2017-05-29

申请人： GIL MEDICAL CENTER

发明人： Seung Kak SHIN ,  Oh Sang KWON ,  Myung Hee CHUNG

IPC分类号： A61K31/708 ,  A61P1/16

摘要： The present invention relates to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis, comprising 8-OHdG or a pharmaceutically acceptable salt thereof, a method for preventing or treating liver fibrosis or liver cirrhosis using the same, and a food composition for ameliorating liver fibrosis or liver cirrhosis, comprising 8-hydroxydeoxyguanosine (8-OHdG) or a pharmaceutically acceptable salt thereof. As use of the pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis can reduce levels of various markers whose expression level increases due to induced liver fibrosis, the pharmaceutical composition can be widely used in the effective prevention or treatment of liver fibrosis or liver cirrhosis induced thereby.

公开(公告)号：US11439656B2

公开(公告)日：2022-09-13

申请号：US16556690

申请日：2019-08-30

申请人： Regents of the University of Minnesota

发明人： DaQing Yang ,  Carston R. Wagner ,  Aniekan Okon

IPC分类号： A01N43/04 ,  A61K31/70 ,  A61K31/708 ,  C07H17/02 ,  A61K31/426 ,  A61K31/365 ,  A61K47/68 ,  A61P35/00 ,  A61K31/675 ,  A61K31/196 ,  A61K31/197 ,  A61K31/175 ,  A61K31/495 ,  A61K31/366

摘要： Described herein are small molecule cap-dependent inhibitors, including the compound of the formula: which compounds that can induce the accumulation of the p53 tumor suppressor protein in cancer cells that still express wild-type p53, as well as methods of using those compounds to, among other things, treat neuroblastoma, pediatric glioblastoma multiforme or breast cancer.